Hi Everyone. We’re in the national press today, with Aileen quoted.
Aileen Feeney, chief executive of the Fertility Network charity, said: 'Knowing whether or not to include fertility add-ons is a very emotionally charged and financially difficult decision to make.
'Patients are often very vulnerable after years of trying to become parents – that's why it is crucial for fertility clinics to behave ethically and not offer false hope or upsell treatment add-ons.'
dailymail.co.uk/news/articl...
Fertility Network is a co-signatory to the HFEA’s consensus statement regarding fertility treatment add-ons, such as endometrial scratch, embryo glue or embryoscope. This consensus statement calls for greater transparency from fertility clinics on fertility treatment add-ons. One of the key principles of the consensus statement is that clinics should only offer treatment add-ons where more than one high quality study demonstrates a treatment add-on to be safe and effective. To make it easier to identify which add-ons have been shown to be effective, the HFEA has a traffic light rating system.
A treatment is red if there is no evidence to show that it is effective and safe.
An amber symbol means there is a small or conflicting body of evidence, which means further research is still required and the technique cannot be recommended for routine use.
A green symbol means there is more than one good quality randomised controlled trial which shows that the procedure is effective and safe.
Currently none of the treatment add-ons the HFEA has assessed have been rated green. This means that the HFEA doesn’t think any of these techniques should be used routinely.
The list of add-ons and their ratings is at hfea.gov.uk/treatments/expl...
Info from the HFEA is here.
hfea.gov.uk/about-us/news-a...
Key principles of the consensus statement are:
•Clinics should only offer treatment add-ons where more than one high quality study demonstrates a treatment add-on to be safe and effective.
•Clinics should stop offering the treatment add-on to patients if concerns are raised regarding safety or effectiveness.
•Patients must be clearly informed of the experimental nature of any treatment add-on which is offered, where there is no robust evidence of its safety and/or effectiveness
•Patients should not be charged extra to take part in a clinical trial.
According to the latest HFEA’s national fertility patient survey:
•For those that had treatment in the last two years, three quarters (74%) had at least one type of treatment add-on, similar to 71% of those in the past five years.
•The most commonly used treatment add-ons for those that used a fertility clinic in the past two years were clinical techniques, such as an endometrial scratch (27%), embryo glue (23%) or embryoscope (22%).